A novel combination for relapsed/refractory multiple myeloma produced responses in about 80% of a heavily treated population, ...

The trial enrolled 531 adult subjects with multiple myeloma who had received at least one previous line of therapy.

Dr. Sattva S. Neelapu discusses how the CAR-T therapy Yescarta impacts the quality of life of patients with R/R indolent non-Hodgkin lymphoma.

If the subcutaneous delivery method gains approval, an advantage daratumumab holds over isatuximab would be removed.

Initial clinical observations suggest high level of T cells reprogramming and CAR-T expansion at the starting dose without lymphodepletion At 28 ...

The combination of a talquetamab and teclistamab induced durable responses among patients with relapsed or refractory ...

Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...

We described the first case reported in the literature of multiple myeloma in a young African woman with Systemic lupus and Sjögren Syndrome. The clinician should consider multiple myeloma in young ...

Both dose levels of modakafusp alfa “resulted in good response rates with similar safety profiles,” according to researchers.

Inobrodib is under clinical development by CellCentric and currently in Phase II for Refractory Multiple Myeloma.

New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma. Sarclisa SC formulation added to Pd for the treatment of R/R MM me ...